2-(tert-butyldimethylsilyloxy)heptadecanenitrile | 1283148-76-4

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: 2-(tert-butyldimethylsilyloxy)heptadecanenitrile
• 英文别名: 2-[Tert-butyl(dimethyl)silyl]oxyheptadecanenitrile
• CAS: 1283148-76-4
• 化学式: C₂₃H₄₇NOSi
• 分子量: 381.718
• InChiKey: MSHKLPXVEBNONW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.38
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.96
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(tert-butyldimethylsilyloxy)heptadecanenitrile 在 sodium azide 、 zinc dibromide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 90.0h， 以79%的产率得到5-(1-((tert-butyldimethylsilyl)oxy)hexadecyl)-1H-tetrazole
  参考文献：
  名称：

  Synthesis of novel ceramide-like penetration enhancers

  摘要：

  Ceramide-like penetration enhancers have been synthesized by isosteric replacements of the 1-hydroxymethyl and amide moieties of natural ceramides. Metabolically more stable oxime and five-membered heterocyclic (1,2,4-oxadiazole, 1,2,4-triazole, tetrazole) analogues are more polar and possess H-bond acceptor properties, which make them potentially useful in optimizing key intermolecular features in interactions between the modified ceramide structures and the lipid layers of stratum corneum. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2011.02.024
• 作为产物：
  描述：

  potassium cyanide 、 十六醛 、 叔丁基氰基二甲基硅烷 在 18-冠醚-6 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以85%的产率得到2-(tert-butyldimethylsilyloxy)heptadecanenitrile
  参考文献：
  名称：

  2-oxothiazole compounds and method of using same for chronic inflammatory disorders

  摘要：

  该发明提供了以下式（I）的化合物，其中X为O或S；R1为H、OH、SH、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤素、卤代C1-6烷基、CN、C1-6烷基、OC1-6烷基、C1-6烷基COOH、C1-6烷基COOC1-6烷基、C2-6烯基、C3-10环烷基、C6-10芳基、C1-6烷基C6-10芳基、杂环烷基、杂芳基、CONH2、CONHC1-6烷基、CON（C1-6烷基）2、OCOC1-6烷基，或者是酸性基团，例如包含羧基、磷酸基、磷酸酯基、硫酸基、磺酸基或四唑基团的基团；R2如R1定义或R1和R2一起形成一个6-成员芳香环，可选地由多达4个R5基团取代；R3为H、卤素（优选氟素），或CHal3（优选CF3）；每个R5如R1定义；V1为共价键，—O—，或C1-20烷基，或C2-20单烯或多不饱和烯基；所述烷基或烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；M1不存在或为C5-10环烷基或C5-15芳基；R4为H、卤素、OH、CN、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤代C1-6烷基、C1-20烷基，或C2-20单烯或多不饱和烯基，所述C1-20烷基或C2-20烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；但条件是，V1M1R4作为一个整体至少提供来自C（R3）基团的4个骨架原子；或其盐、酯、溶剂化合物、N-氧化物或前药；用于治疗慢性炎症症状。

  公开号：

  US09597318B2

文献信息

• 2-oxothiazole compounds and method of using same for chronic inflammatory disorders
  申请人：Kokotos George

  公开号：US09597318B2

  公开（公告）日：2017-03-21

  The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond, —O—, or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.

  该发明提供了以下式（I）的化合物，其中X为O或S；R1为H、OH、SH、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤素、卤代C1-6烷基、CN、C1-6烷基、OC1-6烷基、C1-6烷基COOH、C1-6烷基COOC1-6烷基、C2-6烯基、C3-10环烷基、C6-10芳基、C1-6烷基C6-10芳基、杂环烷基、杂芳基、CONH2、CONHC1-6烷基、CON（C1-6烷基）2、OCOC1-6烷基，或者是酸性基团，例如包含羧基、磷酸基、磷酸酯基、硫酸基、磺酸基或四唑基团的基团；R2如R1定义或R1和R2一起形成一个6-成员芳香环，可选地由多达4个R5基团取代；R3为H、卤素（优选氟素），或CHal3（优选CF3）；每个R5如R1定义；V1为共价键，—O—，或C1-20烷基，或C2-20单烯或多不饱和烯基；所述烷基或烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；M1不存在或为C5-10环烷基或C5-15芳基；R4为H、卤素、OH、CN、硝基、NH2、NHC1-6烷基、N（C1-6烷基）2、卤代C1-6烷基、C1-20烷基，或C2-20单烯或多不饱和烯基，所述C1-20烷基或C2-20烯基基团可选地由O、NH、N（C1-6烷基）、S、SO或SO2中选择的一个或多个杂原子中断；但条件是，V1M1R4作为一个整体至少提供来自C（R3）基团的4个骨架原子；或其盐、酯、溶剂化合物、N-氧化物或前药；用于治疗慢性炎症症状。
• Synthesis of novel ceramide-like penetration enhancers
  作者：Mária Takács、Máté Bubenyák、András Váradi、Balázs Blazics、Péter Horváth、József Kökösi

  DOI：10.1016/j.tetlet.2011.02.024

  日期：2011.4

  Ceramide-like penetration enhancers have been synthesized by isosteric replacements of the 1-hydroxymethyl and amide moieties of natural ceramides. Metabolically more stable oxime and five-membered heterocyclic (1,2,4-oxadiazole, 1,2,4-triazole, tetrazole) analogues are more polar and possess H-bond acceptor properties, which make them potentially useful in optimizing key intermolecular features in interactions between the modified ceramide structures and the lipid layers of stratum corneum. (C) 2011 Elsevier Ltd. All rights reserved.